A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2014
Price : $35 *
At a glance
- Drugs Enclomifene (Primary)
- Indications Hypogonadism; Male infertility
- Focus Pharmacokinetics
- Sponsors Repros Therapeutics
- 09 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.
- 23 Jan 2014 According to ClinicalTrials.gov record planned end date changed from 1 Oct 2013 to 1 May 2014.